MBL International: Generation of Fully Human Monoclonal Antibodies Neutralizing Influenza Virus
Published: Jan 27, 2010
NAGOYA, Japan, Jan. 26 /PRNewswire/ -- Medical & Biological Laboratories Co., Ltd. (MBL), with the collaboration of Osaka University, has successfully generated several fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza virus by utilizing blood samples from volunteers who were inoculated with influenza vaccine.
The therapeutic antibodies were generated by using a special cell line, called SPYMEG. This novel cell line is a human lymphocyte fusion partner, it was co-developed by associate professor Naomasa Yamamoto, Ph. D., of Ohu University and MBL. SPYMEG is the cell line established by the cell fusion of MEG-01 with a murine myeloma cell line. Hybridoma cells of human origin are known to be prone to chromosome deletions. The SPYMEG cell line overcomes that problem, resulting in a higher reliability of cell fusion. Utilization of SPYMEG is a simpler and easier way to generate therapeutic monoclonal antibodies than chimerization, or humanization of mouse monoclonal antibodies generated from immunized mice.
The fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza viruses were generated by the utilization of SPYMEG. The antibodies, originated from the blood of a convalescent volunteer recovering from influenza infection or vaccination, are expected to be effective and very safe.
In the research reagent sector, MBL has been engaged in the worldwide sales of more than 8,000 antibodies that are developed in-house or marketed by foreign and domestic alliance partners. MBL also provides the contract manufacturing of custom-made monoclonal and polyclonal antibodies. MBL has also extended its offering to provide identification kits for mRNA and contract analysis of carbohydrate structure.
MBL is proud to be an antibody manufacturer with commitment to drug discovery focusing on therapeutic monoclonal antibodies.
MBL International, a subsidiary of MBL, is a leading biotechnology company focused on research, development, production and distribution of research reagents for the life science marketplace worldwide.
In 2008, MBL International increased the company's offering of diagnostic products that are used to test for and diagnose severe skin diseases, viral infections and many additional autoimmune diseases. MBL International is your immune system research provider.
CONTACT: Wushouer Ouerkaxi, Business Development, MBL International
Corporation, +1-781-939-6964, firstname.lastname@example.org
Web site: http://www.mblintl.com/